Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
First Extension To assess the effect of treatment up to 5 years with odanacatib on the risk of morphometrically assessed vertebral fractures compared to placebo. To assess the effect of treatment up to 5 years with odanacatib on the risk of clinical hip fractures compared to placebo. To assess the effect of treatment up to 5 years with odanacatib on the risk of non-vertebral clinical fractures compared to placebo. To assess safety and tolerability of treatment up to 5 years with odanacatib 50 mg once weekly compared to placebo. Second extension: To assess long-term changes from baseline in total hip BMD during 10 years of treatment with odanacatib 50 mg once-weekly in postmenopausal osteoporotic women previously treated with once-weekly odanacatib for at least 5 years (cumulative of base study and 1st extension study, i.e randomized to odanacatib during the base study To assess safety and tolerability of long-term treatment with odanacatib 50 mg once-weekly.
Inclusion criteria
- Postmenopausal osteoporosis